These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37053216)

  • 1. Synonymous alterations of cancer-associated Trp53 CpG mutational hotspots cause fatal developmental jaw malocclusions but no tumors in knock-in mice.
    Epstein RJ; Lin FPY; Brink RA; Blackburn J
    PLoS One; 2023; 18(4):e0284327. PubMed ID: 37053216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Damage-inducible intragenic demethylation of the human TP53 tumor suppressor gene is associated with transcription from an alternative intronic promoter.
    Blackburn J; Roden DL; Ng R; Wu J; Bosman A; Epstein RJ
    Mol Carcinog; 2016 Dec; 55(12):1940-1951. PubMed ID: 26676339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unveiling the methylation status of CpG dinucleotides in the substituted segment of the human p53 knock-in (Hupki) mouse genome.
    Kim SI; Hollstein M; Pfeifer GP; Besaratinia A
    Mol Carcinog; 2010 Dec; 49(12):999-1006. PubMed ID: 20945503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation.
    Nguyen CT; Gonzales FA; Jones PA
    Nucleic Acids Res; 2001 Nov; 29(22):4598-606. PubMed ID: 11713309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation.
    Pogribny IP; James SJ
    Cancer Lett; 2002 Feb; 176(2):169-74. PubMed ID: 11804744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers.
    Tornaletti S; Pfeifer GP
    Oncogene; 1995 Apr; 10(8):1493-9. PubMed ID: 7731703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A WW domain binding region in methyl-CpG-binding protein MeCP2: impact on Rett syndrome.
    Buschdorf JP; Strätling WH
    J Mol Med (Berl); 2004 Feb; 82(2):135-43. PubMed ID: 14618241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-halogenated pyrimidine lesions within a CpG sequence context mimic 5-methylcytosine by enhancing the binding of the methyl-CpG-binding domain of methyl-CpG-binding protein 2 (MeCP2).
    Valinluck V; Liu P; Kang JI; Burdzy A; Sowers LC
    Nucleic Acids Res; 2005; 33(9):3057-64. PubMed ID: 15917437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal histone modifications on the inactive X chromosome in ICF and Rett syndrome cells: implications for methyl-CpG binding proteins.
    Gartler SM; Varadarajan KR; Luo P; Canfield TK; Traynor J; Francke U; Hansen RS
    BMC Biol; 2004 Sep; 2():21. PubMed ID: 15377381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers.
    Yoon JH; Smith LE; Feng Z; Tang M; Lee CS; Pfeifer GP
    Cancer Res; 2001 Oct; 61(19):7110-7. PubMed ID: 11585742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of conserved cis-regulatory elements in the post-transcriptional regulation of the human MECP2 gene involved in autism.
    Bagga JS; D'Antonio LA
    Hum Genomics; 2013 Sep; 7(1):19. PubMed ID: 24040966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
    Nguyen C; Liang G; Nguyen TT; Tsao-Wei D; Groshen S; Lübbert M; Zhou JH; Benedict WF; Jones PA
    J Natl Cancer Inst; 2001 Oct; 93(19):1465-72. PubMed ID: 11584062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation in the gene body influences MeCP2-mediated gene repression.
    Kinde B; Wu DY; Greenberg ME; Gabel HW
    Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15114-15119. PubMed ID: 27965390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting chromatin organization of CpG islands and exons in the human genome.
    Choi JK
    Genome Biol; 2010; 11(7):R70. PubMed ID: 20602769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuronal non-CG methylation is an essential target for MeCP2 function.
    Tillotson R; Cholewa-Waclaw J; Chhatbar K; Connelly JC; Kirschner SA; Webb S; Koerner MV; Selfridge J; Kelly DA; De Sousa D; Brown K; Lyst MJ; Kriaucionis S; Bird A
    Mol Cell; 2021 Mar; 81(6):1260-1275.e12. PubMed ID: 33561390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methyl-CpG binding proteins in the nervous system.
    Fan G; Hutnick L
    Cell Res; 2005 Apr; 15(4):255-61. PubMed ID: 15857580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of CpG methylation on recognition of DNA by the tumour suppressor p53.
    Petrovich M; Veprintsev DB
    J Mol Biol; 2009 Feb; 386(1):72-80. PubMed ID: 19084536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG.
    Klose RJ; Sarraf SA; Schmiedeberg L; McDermott SM; Stancheva I; Bird AP
    Mol Cell; 2005 Sep; 19(5):667-78. PubMed ID: 16137622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger.
    Ballestar E; Esteller M
    Biochem Cell Biol; 2005 Jun; 83(3):374-84. PubMed ID: 15959563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebellar gene expression profiles of mouse models for Rett syndrome reveal novel MeCP2 targets.
    Jordan C; Li HH; Kwan HC; Francke U
    BMC Med Genet; 2007 Jun; 8():36. PubMed ID: 17584923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.